trending Market Intelligence /marketintelligence/en/news-insights/trending/CCa7sLl4SQF4t4gtWgULQg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Luminex Corp. has completed the acquisition of Merck KGaA's cell analysis equipment provider MilliporeSigma in a $75 million cash, stock and asset deal.

The acquisition expands the Austin, Texas-based company's footprint in life science research and broadens its existing offering of flow-based detection systems. The portfolio includes flow cytometry products sold under the brand names Amnis, for cell-based analysis, and Guava, which are high-performance systems based on microcapillary technologies.

Luminex expects the acquisition to contribute $40 million to $50 million toward its 2019 revenues.

Cantor Fitzgerald & Co. acted as financial adviser and Smith Gambrell & Russell LLP served as legal counsel to Luminex.